Stay updated on Nivolumab and SRS in Recurrent Meningioma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab and SRS in Recurrent Meningioma Clinical Trial page.

Latest updates to the Nivolumab and SRS in Recurrent Meningioma Clinical Trial page
- Check3 days agoChange DetectedAdded a new Locations section listing participating sites across Arizona, California, Colorado, Florida, Kansas, Maryland, Minnesota, Missouri, Nebraska, New York, North Carolina, Pennsylvania, Texas, and Utah; updated the page revision to v3.3.3.SummaryDifference1%

- Check10 days agoChange DetectedAdded study record update dates 2025-12-16 and 2025-12-13, and removed dates 2025-12-09 and 2025-12-06 from the Study Record Dates. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check17 days agoChange DetectedNew update dates were added (2025-12-09, 2026-01-06, 2025-12-06, 2025-12) and older timestamps removed, with no substantive changes to the study details.SummaryDifference0.2%

- Check24 days agoChange DetectedAdded explicit primary and secondary objectives for the Phase I/II trial, including maximum tolerated combination safety and MRI-based objective response rate, and extended follow-up timing (treatment start to at least two years) with associated imaging and biomarker assessments. Also clarified or updated study procedures (MRI, blood sample collection, echocardiography) and removed certain earlier timepoint references such as 'Up to 100 days'.SummaryDifference0.5%

- Check31 days agoChange DetectedRevision updated to v3.3.2; previous v3.2.0 has been removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check38 days agoChange DetectedThe only change is the removal of a general government funding status notice; there are no edits to core study information, eligibility criteria, or trial data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

Stay in the know with updates to Nivolumab and SRS in Recurrent Meningioma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab and SRS in Recurrent Meningioma Clinical Trial page.